CGT
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SUSTAINABILITY
MORE
EXPERT VIEWS
INTERVIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK 2026
Subscribe
CGT
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SUSTAINABILITY
MORE
EXPERT VIEWS
INTERVIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK 2026
SEARCH
SEARCH
advanced search
Marco Laackmann
Director, Inhalation Technology
Is this your profile?
About
Marco Laackmann is Director of Inhalation Technology at Harro Höfliger.
Contributions
ROUNDTABLE
ROUNDTABLE: CAPSULE-BASED DRY POWDER INHALERS
Frédérique Bordes-Picard of Lonza, Marco Franza of Berry, Mirjam Kobler of Meggle, and Marco Laackmann of Harro Höfliger, discuss the accelerating development potential of capsule-based dry powder inhalers (DPIs) and the potential of these effective and efficient drug delivery devices in the modern drug delivery market.
More contributions
RESPIRATORY
PRACTICAL INSIGHTS INTO LACTOSE-BASED DPI FORMULATIONS, WITH & WITHOUT MAGNESIUM STEARATE
Partners DFE Pharma, Hosokawa Micron and Harro Höfliger describe their unique multidisciplinary study into lactose-based DPI formulations including magnesium stearate, whose findings will give generic players a head-start in the development process so that they can tap into this rapidly growing market. The three companies announce that they will be presenting the key insights from their research to interested parties during a joint webinar on the June 30th, 2020.
Top